ACT Genomics Acquires MC Diagnostics

ICON plc Acquires MolecularMD Corporation

February 21, 2019

Healthcare Services

ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.

ACT Laboratories Acquires CDX Analytics

September 28, 2022

Healthcare Services

ACT Laboratories, Inc. has agreed to acquire CDX Analytics, LLC to expand its cannabis and hemp testing footprint into Massachusetts. ACT Labs — majority owned by Intrinsic Capital Partners — said the deal (subject to Massachusetts regulatory approval) will extend its multistate laboratory network and enhance capacity and scientific capabilities for local cultivators, processors and dispensaries.

R-Biopharm AG Acquires AusDiagnostics

June 7, 2022

Biotechnology

German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.

CERTANIA Acquires Bioarray Genetic Diagnosis

July 9, 2025

Healthcare Services

CERTANIA, a Munich-based Testing, Inspection and Certification (TIC) group, has acquired Spanish genetic diagnostics lab Bioarray, which will join CERTANIA’s global network. Bioarray — headquartered in Elche (Alicante) — will continue to be led by cofounder Andrés Antón Salas and will leverage CERTANIA’s platform to expand its genomic diagnostics and research services internationally.

Castle Biosciences Acquires AltheaDx

April 26, 2022

Healthcare Services

Castle Biosciences (Nasdaq: CSTL) completed the acquisition of AltheaDx, a San Diego-based commercial-stage pharmacogenomics company and maker of the IDgenetix mental-health PGx test. Castle paid $65.0 million in initial consideration (split $32.5M cash and $32.5M stock) and may pay up to an additional $75.0 million tied to performance and milestone achievements; AltheaDx becomes a wholly owned subsidiary and IDgenetix now has expanded Medicare coverage for multiple mental health conditions.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.